tiprankstipranks
Trending News
More News >
Extrawell Pharmaceutical Holdings Limited (HK:0858)
:0858
Hong Kong Market

Extrawell Pharmaceutical Holdings Limited (0858) Stock Statistics & Valuation Metrics

Compare
0 Followers

Total Valuation

Extrawell Pharmaceutical Holdings Limited has a market cap or net worth of HK$121.89M. The enterprise value is HK$653.51M.
Market CapHK$121.89M
Enterprise ValueHK$653.51M

Share Statistics

Extrawell Pharmaceutical Holdings Limited has 2,390,000,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,390,000,200
Owned by Insiders
Owned by Institutions

Financial Efficiency

Extrawell Pharmaceutical Holdings Limited’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -0.53%.
Return on Equity (ROE)-0.15
Return on Assets (ROA)-0.13
Return on Invested Capital (ROIC)-0.53%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee364.80K
Profits Per Employee-1.01M
Employee Count162
Asset Turnover0.05
Inventory Turnover4.17

Valuation Ratios

The current PE Ratio of Extrawell Pharmaceutical Holdings Limited is -0.43. Extrawell Pharmaceutical Holdings Limited’s PEG ratio is -1.35.
PE Ratio-0.43
PS Ratio0.00
PB Ratio0.21
Price to Fair Value0.06
Price to FCF-47.06
Price to Operating Cash Flow49.82
PEG Ratio-1.35

Income Statement

In the last 12 months, Extrawell Pharmaceutical Holdings Limited had revenue of 59.10M and earned -162.95M in profits. Earnings per share was -0.07.
Revenue59.10M
Gross Profit28.78M
Operating Income-6.53M
Pretax Income-159.51M
Net Income-162.95M
EBITDA-129.52M
Earnings Per Share (EPS)-0.07

Cash Flow

In the last 12 months, operating cash flow was 2.81M and capital expenditures -1.20M, giving a free cash flow of 1.61M billion.
Operating Cash Flow2.81M
Free Cash Flow1.61M
Free Cash Flow per Share<0.01

Dividends & Yields

Extrawell Pharmaceutical Holdings Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.55
52-Week Price Change25.00%
50-Day Moving Average0.05
200-Day Moving Average0.05
Relative Strength Index (RSI)49.83
Average Volume (3m)819.33K

Important Dates

Extrawell Pharmaceutical Holdings Limited upcoming earnings date is Jun 27, 2025, TBA Not Confirmed.
Last Earnings DateNov 29, 2024
Next Earnings DateJun 27, 2025
Ex-Dividend Date

Financial Position

Extrawell Pharmaceutical Holdings Limited as a current ratio of 3.45, with Debt / Equity ratio of 80.01%
Current Ratio3.45
Quick Ratio3.31
Debt to Market Cap1.69
Net Debt to EBITDA-0.21
Interest Coverage Ratio-0.35

Taxes

In the past 12 months, Extrawell Pharmaceutical Holdings Limited has paid 2.13M in taxes.
Income Tax2.13M
Effective Tax Rate-0.01

Enterprise Valuation

Extrawell Pharmaceutical Holdings Limited EV to EBITDA ratio is -0.74, with an EV/FCF ratio of -19.65.
EV to Sales1.63
EV to EBITDA-0.74
EV to Free Cash Flow-19.65
EV to Operating Cash Flow-26.05

Balance Sheet

Extrawell Pharmaceutical Holdings Limited has HK$870.44M in cash and marketable securities with HK$130.18M in debt, giving a net cash position of -HK$740.26M billion.
Cash & Marketable SecuritiesHK$870.44M
Total DebtHK$130.18M
Net Cash-HK$740.26M
Net Cash Per Share-HK$0.31
Tangible Book Value Per ShareHK$0.46

Margins

Gross margin is 42.91%, with operating margin of -11.04%, and net profit margin of -275.73%.
Gross Margin42.91%
Operating Margin-11.04%
Pretax Margin-269.91%
Net Profit Margin-275.73%
EBITDA Margin-219.16%
EBIT Margin-234.24%

Analyst Forecast

The average price target for Extrawell Pharmaceutical Holdings Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast-12.93%
EPS Growth Forecast

Scores

Smart Score7
AI Score50
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis